

SUPPLEMENTARY MATERIAL

Table 1. Selection criteria for Alergodata Registry patients.

Inclusion criteria
<ul style="list-style-type: none">• Adult patients or children over six years with a diagnosis of severe asthma, whether or not treated with biological drugs according to the SPC approved in Spain*.• Patients diagnosed with chronic rhinosinusitis with nasal polyps and/or chronic urticaria and/or moderate to severe atopic dermatitis that receive treatment with biological drugs according to the SPC approved in Spain*†.• Patients that are seen in allergology clinics.• Patients who have signed informed consent to participate in the study.
Exclusion criteria
<ul style="list-style-type: none">• Patients with a medical or psychological disorder that could limit their ability to understand and/or answer questions and complete questionnaires or patients who, in the opinion of the investigator, are unlikely to collaborate sufficiently.

* All biological drugs approved in the SPC approved in Spain at the time of the inclusion of the patient to the study may be included in the registry.

† The age of inclusion will be determined according to the SPC approved in Spain* for the different biological drugs in each disease.

Table 2. Most relevant clinical and socio-demographic variables of the patients included in the Alergodata Registry.

Clinical and socio-demographic variables	Severe Asthma	Severe Asthma^a with CRSwNP
Age	N=170	N=30
Adults, Mean \pm SD (n)	50.6 \pm 14.4 (n=158)	51.4 \pm 12.4
Children, Mean \pm SD (n)	13.8 \pm 3.8 (n=12)	N/A
Sex	N=170	N=30
Woman (%)	64.1%	50.0%
Body Mass Index (kg/m²), Median (Q1; Q3)	27.0 (23.8; 32.1)	25.3 (23.6,29.2)
Smoking habits	N=158	N=29
Non-smoking, n (%)	150.0 (94.90%)	28.0 (96.6%)
Former smokers, n (%)	41.0 (27.30%)	8.0 (28.6%)
Comorbidities (%)	N=170	N=30
CRSwNP ^a	44.1%	N/A
CRS without nasal polyps	7.1%	N/A
Atopic Dermatitis ^a	10.0%	10.0%
Rhinitis	68.0%	65.5%
Gastroesophageal reflux	17.1%	10.0%
Psychiatric disturbance	11.8%	6.67%
Respiratory disease exacerbated by NSAIDs	18.2%	50.0%
Bronchiectasis	7.7%	10.0%
Obstructive sleep apnea	7.1%	6.9%
Exacerbations, Mean \pm SD	1.9 \pm 2.3 (N=143)	N/A
Level of asthma control, n (%)	N=132	
Controlled	27.0 (20.5%)	N/A
Uncontrolled	105.0 (79.5%)	N/A
Need for admission to ICU	5.0 (3.4%)	N/A
Phenotypes of asthma (%)	N=146	N=22
Eosinophilic (T2)	47.9%	77.3%
Allergic (T2)	50.7%	22.7%
Non-eosinophilic	1.4%	0.0%
Symptoms trigger, n (%)	N=137	N=18
Infections, n (%)	34.0 (24.8%)	4 (22.2%)
Irritants, n (%)	24.0 (17.5%)	3 (16.7%)
Allergens, n (%)	62.0 (44.5%)	6 (33.3%)
Exercise, n (%)	9.0 (6.57%)	1 (5.56%)
Others**, n (%)	8.0 (6.57%)	4 (22.2%)
Inflammatory characteristics		
Eosinophils in peripheral blood (cell/mm ³), Mean \pm SD.	519.0 \pm 577.0 (N=122)	
Eosinophils in sputum (%)	20.0% (N=1)	
IgE Total serum (kU/L), Mean \pm SD.	551.0 \pm 775.0 (N=125)	
FE _{NO} (ppb), Mean \pm SD.	55.2 \pm 53.9 (N=83)	

Conventional treatments, %		N=170	N=23
ICS/LABA combination	93.5%		96.3%
SABA	62.4%		27%
Montelukast	77.7%		59.3%
LAMA (one or more devices)	55.9%		44.4%
Intranasal corticosteroids	58.2%		92.6% %
Antihistamines	55.3%		55.6%
Allergen-specific immunotherapy (ASIT)	10.1% (N=169)		8.0%
Systemic corticosteroids	24.7%		7.4% (N=16)
Cumulative annual dose (prednisone), Mean ± SD	839.0 ± 3801.0 (N=131)		
Clinically relevant allergic sensitization, (%)	65.9% (N=170)		60.0% (N=30)
Prescribed biologic treatment, % (N)			
Omalizumab	28.6% (N=168)		12.5% (N=24)
Dupilumab	27.9% (N=165)		69.6% (N=23)
Mepolizumab	23.4% (N=167)		20.8% (N=24)
Benralizumab	20.4% (N=157)		4.2% (N=24)
Reslizumab	3.8% (N=158)		4.0% (N=25)
Questionnaires			
ACT (asthma), Mean ± SD	15.5 ± 5.2 (N=132)		N/A
ACT (asthma and CRSwNP), Mean ± SD	N/A		15.4 ± 5.4 (N=20)
SNOT (asthma and CRSwNP), Mean ± SD	N/A		50.9 ± 25.3 (N=23)
TPS (asthma and CRSwNP), Mean ± SD	N/A		3.9 ± 2.7 (N=13)

^a(with or without associated biologic treatment)

*Others: NSAIDs, metamizol, eosinophilic esophagitis, lipid transfer protein, pyrazonic medicines, penicillin, prophyrins, thiomersal, feathers.

N/A, Not applicable; CRSwNP, chronic rhinosinusitis with nasal polyps; CRS, chronic rhinosinusitis; COPD, chronic obstructive pulmonary disease; ICS, Inhaled corticosteroids; LABA, Long-acting beta-agonists; SABA, Short-acting beta-agonists; LAMA, long acting muscarinic antagonist;